NASDAQ : NVCT
Nuvectis Pharma, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 18.57 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 605.04M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 9.22M | 9.42M | 6.93M | 7.52M | 6.01M | 3.35M |
| Research & Development | 19.65M | 18.15M | 12.92M | 14.38M | 12.03M | 2.44M |
| Operating Expenses | 28.87M | 27.57M | 19.85M | 21.90M | 18.03M | 5.79M |
| Operating Income | -28.87M | -27.57M | -19.85M | -21.90M | -18.03M | -5.79M |
| Interest & Investment Income | 1.02M | 1.13M | 847.00K | 637.00K | 149.00K | 4.00K |
| EBT Excluding Unusual Items | -27.85M | -26.44M | -19.00M | -21.26M | -17.89M | -5.79M |
| Other Unusual Items | -1.00M | -1.20M | -7.10M | |||
| Pretax Income | -27.85M | -26.44M | -19.00M | -22.26M | -19.09M | -12.89M |
| Net Income | -27.85M | -26.44M | -19.00M | -22.26M | -19.09M | -12.89M |
| Preferred Dividends & Other Adjustments | 2.43M | 2.43M | ||||
| Net Income to Common | -30.27M | -28.87M | -19.00M | -22.26M | -19.09M | -12.89M |
| Shares Outstanding (Basic) | 23.21M | 21.81M | 17.11M | 15.56M | 12.66M | 4.27M |
| Shares Outstanding (Diluted) | 23.21M | 21.81M | 17.11M | 15.56M | 12.66M | 4.27M |
| EPS (Basic) | -1.30 | -1.32 | -1.11 | -1.43 | -1.51 | -3.02 |
| EPS (Diluted) | -1.30 | -1.32 | -1.11 | -1.43 | -1.51 | -3.02 |
| EBIT | -28.87M | -27.57M | -19.85M | -21.90M | -18.03M | -5.79M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 22.16M | 31.63M | 18.53M | 19.13M | 19.99M | 5.74M |
| Cash & Short-Term Investments | 22.16M | 31.63M | 18.53M | 19.13M | 19.99M | 5.74M |
| Other Current Assets | 216.00K | 75.00K | 74.00K | 59.00K | 412.00K | 91.00K |
| Total Current Assets | 22.38M | 31.71M | 18.61M | 19.18M | 20.41M | 5.83M |
| Long-Term Deferred Charges | 824.00K | |||||
| Total Assets | 22.38M | 31.71M | 18.61M | 19.18M | 20.41M | 6.66M |
| Accounts Payable | 5.18M | 6.27M | 2.50M | 2.77M | 2.91M | 1.06M |
| Accrued Expenses | 6.72M | 7.02M | 6.40M | 4.21M | 2.83M | 537.00K |
| Other Current Liabilities | 1.39M | 450.00K | 824.00K | |||
| Total Current Liabilities | 13.29M | 13.30M | 8.89M | 6.98M | 6.19M | 2.42M |
| Total Liabilities | 13.29M | 13.30M | 8.89M | 6.98M | 6.19M | 2.42M |
| Additional Paid-In Capital | 121.84M | 118.10M | 82.96M | 66.45M | 46.20M | 1.89M |
| Retained Earnings | -112.76M | -99.69M | -73.25M | -54.24M | -31.98M | -12.90M |
| Total Common Equity | 9.08M | 18.41M | 9.71M | 12.20M | 14.22M | -11.01M |
| Shareholders' Equity | 9.08M | 18.41M | 9.71M | 12.20M | 14.22M | 4.24M |
| Total Liabilities & Equity | 22.38M | 31.71M | 18.61M | 19.18M | 20.41M | 6.66M |
| Net Cash (Debt) | 22.16M | 31.63M | 18.53M | 19.13M | 19.99M | 5.74M |
| Net Cash Per Share | 0.95 | 1.45 | 1.08 | 1.23 | 1.58 | 1.35 |
| Filing Date Shares Outstanding | 32.58M | 26.49M | 23.39M | 17.77M | 14.75M | 12.72M |
| Total Common Shares Outstanding | 26.69M | 25.68M | 19.50M | 17.42M | 14.64M | 4.51M |
| Working Capital | 9.08M | 18.41M | 9.71M | 12.20M | 14.22M | 3.41M |
| Book Value Per Share | 0.34 | 0.72 | 0.50 | 0.70 | 0.97 | -2.44 |
| Tangible Book Value | 9.08M | 18.41M | 9.71M | 12.20M | 14.22M | -11.01M |
| Tangible Book Value Per Share | 0.34 | 0.72 | 0.50 | 0.70 | 0.97 | -2.44 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -27.85M | -26.44M | -19.00M | -22.26M | -19.09M | -12.89M |
| Stock-Based Compensation | 6.49M | 6.03M | 4.86M | 4.71M | 1.71M | 1.89M |
| Change in Accounts Payable | 207.00K | 3.78M | -273.00K | -139.00K | 1.85M | 1.58M |
| Change in Other Net Operating Assets | 1.64M | 625.00K | 2.17M | 1.74M | 1.97M | -91.00K |
| Operating Cash Flow | -19.51M | -16.01M | -12.25M | -15.95M | -13.56M | -9.50M |
| Issuance of Common Stock | 15.37M | 31.21M | 12.04M | 16.48M | 31.88M | |
| Other Financing Activities | -493.00K | -2.10M | -382.00K | -1.39M | -4.07M | |
| Financing Cash Flow | 14.88M | 29.11M | 11.65M | 15.09M | 27.81M | 15.25M |
| Net Cash Flow | -4.63M | 13.10M | -593.00K | -867.00K | 14.25M | 5.74M |
| Levered Free Cash Flow | -8.89M | -6.83M | -5.61M | -7.83M | -6.12M | |
| Unlevered Free Cash Flow | -8.89M | -6.83M | -5.61M | -7.83M | -6.12M | |
| Change in Working Capital | 1.84M | 4.40M | 1.90M | 1.60M | 3.82M | 1.49M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 622.96M | 193.39M | 104.53M | 144.50M | 109.82M | |
| Enterprise Value | 600.80M | 157.95M | 87.36M | 122.44M | 86.18M | |
| Last Close Price | 18.48 | 7.55 | 5.41 | 8.34 | 7.50 | |
| PB Ratio | 54.32 | 10.50 | 10.76 | 11.84 | 7.72 | |
| P/TBV Ratio | 66.80 | 10.50 | 10.76 | 11.84 | 7.72 | |
| Net Debt / Equity Ratio | -2.44 | -1.72 | -1.91 | -1.57 | -1.41 | -1.35 |
| Quick Ratio | 1.67 | 2.38 | 2.08 | 2.74 | 3.23 | 2.37 |
| Current Ratio | 1.68 | 2.38 | 2.09 | 2.75 | 3.30 | 2.41 |
| Return on Equity (ROE) | -214.58% | -188.03% | -173.41% | -168.51% | -206.81% | -609.74% |
| Return on Assets (ROA) | -73.07% | -68.50% | -65.64% | -69.14% | -83.30% | |
| Return on Capital Employed (ROCE) | -317.90% | -149.80% | -204.30% | -179.50% | -126.80% | -136.70% |
| Earnings Yield | -6.82% | -13.67% | -18.18% | -15.40% | -17.38% | |
| Buyback Yield / Dilution | -21.66% | -27.46% | -10.01% | -22.90% | -196.55% | -9.44% |